Study Compares Gender Parity with Other Industries
The Healthcare Businesswomen’s Association (HBA), a global not-for-profit organization dedicated to furthering the advancement and impact of women in the business of healthcare, points to a paper recently published by McKinsey, it’s annual Women in the Workplace study. Data from the study looks deeper into how women fare on compensation, promotion rates, and positions compared to peers in other industry segments.
Overall, the news is favorable for women in the business of healthcare-including those working in pharma, medical devices, and biotech.
Key takeaways from the McKinsey report include:
- Over 60 percent of employees entering the healthcare industry are women
- Healthcare draws 50 percent of STEM graduates
- Rates of promotion are higher with healthcare outperforming almost all other sectors in the first critical promotion step from entry level to manager
- Women are better represented in healthcare at all levels than in corporate America overall:
- 42 percent of VP roles compared to 29 percent
- 31 percent of senior VP roles compared to 23 percent
- 30 percent of C-suite roles compared to 22 percent
- Women in healthcare reported receiving more of what they requested in compensation negotiations more often than men did
You can read the full Women in the Healthcare Industry report here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
